Last SFr.49.40 CHF
Change Today +0.25 / 0.51%
Volume 2.3K
BANB On Other Exchanges
SIX Swiss Ex
As of 11:43 AM 07/28/14 All times are local (Market data is delayed by at least 15 minutes).

bachem holding ag-reg b (BANB) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/11/14 - SFr.50.90
52 Week Low
09/20/13 - SFr.39.73
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BACHEM HOLDING AG-REG B (BANB)

Related News

No related news articles were found.

bachem holding ag-reg b (BANB) Related Businessweek News

No Related Businessweek News Found

bachem holding ag-reg b (BANB) Details

Bachem Holding AG, a technology-based biochemicals company, provides various services to the pharmaceutical and biotechnology industries primarily in Europe and North America. The company is engaged in the process development; and the manufacture of peptides and complex organic molecules as active pharmaceutical ingredients (APIs), as well as biochemicals for research purposes. It offers research products, which include catalog products comprising amino acid derivatives, peptides, non-peptidic biochemicals, immunology products, and other biochemicals in various packaging sizes for peptide research, small scale peptide synthesis, or other research area; Melusine venom libraries, including common venom discovery collections, rare venom discovery collections, rare spider venom collections, and snake venom collections for discovering new drug candidates; sterile peptides under the Clinalfa brand; and custom synthesis service for peptides and amino acids. The company also provides API products, including generic APIs that are used in the fields of cancer, diabetes, obesity, fertility, and others; and new chemical entities. In addition, the company offers customer support services, such as formulation development; sterile tox-vials; compatibility studies; stress tests; post-release stability studies; chemistry, manufacturing, and control documentation for Investigational Medicinal Product Dossier and Investigational New Drug services; and other services. Bachem Holding AG was founded in 1971 and is headquartered in Bubendorf, Switzerland.

649 Employees
Last Reported Date: 03/21/14
Founded in 1971

bachem holding ag-reg b (BANB) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: SFr.398.0K
Compensation as of Fiscal Year 2013.

bachem holding ag-reg b (BANB) Key Developments

Bachem Holding AG Presents at ChinaBio(R) Partnering Forum 2014, May-07-2014

Bachem Holding AG Presents at ChinaBio(R) Partnering Forum 2014, May-07-2014 . Venue: Kempinski Hotel Suzhou, Suzhou, China.

Bachem Group Reports Earnings Results for the Year 2013; Proposes Dividend, Payable on May 6, 2014

Bachem Group reported earnings results for the year 2013. For the year, the company’s sales were CHF 170.7 million against CHF 157.3 million a year ago. EBITDA was CHF 47.4 million against CHF 44.7 million a year ago. EBIT was CHF 29.5 million against CHF 22.3 million a year ago. Net income was CHF 23.6 million against CHF 15.6 million a year ago. Earnings per share were CHF 1.75 against CHF 1.15 a year ago. Cash flow from operating activities was CHF 49.2 million against CHF 36.9 million a year ago. Return on equity was 7% compared to 4.6% a year ago. The Board of Directors will propose increasing the dividend to CHF 1.75 compared to CHF 1.50 for the same period last year at the Annual General Meeting to be held on April 28, 2014.

Bachem Group Reports Earnings Results for First Half of 2013; Provides Earnings Outlook for the Second Half and Full Year 2013

Bachem Group reported earnings results for first half of 2013. For the period, the company’s sales were CHF 81.8 million against CHF 76.2 million a year ago. EBITDA was CHF 21.7 million against CHF 20.0 million a year ago. EBIT was CHF 12.8 million against CHF 10.8 million a year ago. Net income was CHF 10.4 million against CHF 7.3 million a year ago. EPS was CHF 0.77 against CHF 0.54 a year ago. Cash flow from operating activities was CHF 25.0 million against CHF 8.2 million a year ago. The company is confident that it will achieve the forecast increase in sales compared to the previous year. In view of this pleasing development in the first half, the company is expecting another year-on-year increase in profits. The renewed improvement of profitability achieved in the first half is expected to carry forth in the second half.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BANB:SW SFr.49.40 CHF +0.25

BANB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BANB.
View Industry Companies

Industry Analysis


Industry Average

Valuation BANB Industry Range
Price/Earnings 27.7x
Price/Sales 3.8x
Price/Book 1.9x
Price/Cash Flow 14.0x
TEV/Sales 1.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BACHEM HOLDING AG-REG B, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at